U.S., Dec. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07302035) titled 'A First-in-Human Safety and Pharmacokinetic Trial of GenSci142 Administered as Single Ascending Doses in Healthy Chinese Women' on Nov. 27.
Brief Summary: This is a Phase Ia single-center, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, Pharmacokinetic of GenSci142 in Chinese healthy women.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Bacterial Vaginosis
Intervention:
DRUG: GenSci142
Vaginal insert
DRUG: Placebo GenSci142
Vaginal insert
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndi...